Literature DB >> 26859106

Differential Effects of Teriparatide and Denosumab on Intact PTH and Bone Formation Indices: AVA Osteoporosis Study.

David W Dempster1, Hua Zhou1, Robert R Recker1, Jacques P Brown1, Christopher P Recknor1, E Michael Lewiecki1, Paul D Miller1, Sudhaker D Rao1, David L Kendler1, Robert Lindsay1, John H Krege1, Jahangir Alam1, Kathleen A Taylor1, Boris Janos1, Valerie A Ruff1.   

Abstract

We compared effects of teriparatide and denosumab on PTH, bone turnover markers, and bone histomorphometry in osteoporotic postmenopausal women. The findings were inconsistent with an early indirect anabolic effect of denosumab.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26859106      PMCID： PMC4880160          DOI： 10.1210/jc.2015-4181

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN： 0021-972X            Impact factor:   5.958


  32 in total

1.  Circulating semaphorin-4D and plexin-B1 levels in postmenopausal women with low bone mass: the 3-month effect of zoledronic acid, denosumab or teriparatide treatment.

Authors:  Athanasios D Anastasilakis; Stergios A Polyzos; Polyzois Makras; Athina Gkiomisi; Grigorios Sakellariou; Matthaios Savvidis; Athanasios Papatheodorou; Panagiotis Kokkoris; Evangelos Terpos
Journal:  Expert Opin Ther Targets       Date:  2014-11-14       Impact factor: 6.902

2.  Teriparatide increases bone formation in modeling and remodeling osteons and enhances IGF-II immunoreactivity in postmenopausal women with osteoporosis.

Authors:  Yanfei L Ma; Qingqiang Zeng; David W Donley; Louis-Georges Ste-Marie; J Christopher Gallagher; Gail P Dalsky; Robert Marcus; Erik Fink Eriksen
Journal:  J Bone Miner Res       Date:  2006-06       Impact factor: 6.741

3.  The effects of programmed administration of human parathyroid hormone fragment (1-34) on bone histomorphometry and serum chemistry in rats.

Authors:  H Dobnig; R T Turner
Journal:  Endocrinology       Date:  1997-11       Impact factor: 4.736

4.  Difference in label length between demethylchlortetracycline and oxytetracycline: implications for the interpretation of bone histomorphometric data.

Authors:  A M Parfitt; J Foldes; A R Villanueva; M S Shih
Journal:  Calcif Tissue Int       Date:  1991-02       Impact factor: 4.333

Review 5.  Issues in modern bone histomorphometry.

Authors:  R R Recker; D B Kimmel; D Dempster; R S Weinstein; T J Wronski; D B Burr
Journal:  Bone       Date:  2011-07-23       Impact factor: 4.398

6.  Transient secondary hyperparathyroidism following intravenous infusion of zoledronic acid.

Authors:  Stergios A Polyzos; Athanasios D Anastasilakis; Evangelos Terpos
Journal:  Support Care Cancer       Date:  2009-07-30       Impact factor: 3.603

7.  Double and quadruple tetracycline labeling of bone: impact of the label itself.

Authors:  Robert Lindsay; Hua Zhou; Felicia Cosman; Jeri Nieves; David Dempster
Journal:  J Bone Miner Res       Date:  2013-01       Impact factor: 6.741

Review 8.  The effect of antiresorptives on bone quality.

Authors:  Robert R Recker; Laura Armas
Journal:  Clin Orthop Relat Res       Date:  2011-08       Impact factor: 4.176

9.  Parathyroid hormone changes following denosumab treatment in postmenopausal osteoporosis.

Authors:  Polyzois Makras; Stergios A Polyzos; Athanasios Papatheodorou; Panagiotis Kokkoris; Daniel Chatzifotiadis; Athanasios D Anastasilakis
Journal:  Clin Endocrinol (Oxf)       Date:  2013-04-01       Impact factor: 3.478

10.  The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study.

Authors:  S Papapoulos; K Lippuner; C Roux; C J F Lin; D L Kendler; E M Lewiecki; M L Brandi; E Czerwiński; E Franek; P Lakatos; C Mautalen; S Minisola; J Y Reginster; S Jensen; N S Daizadeh; A Wang; M Gavin; C Libanati; R B Wagman; H G Bone
Journal:  Osteoporos Int       Date:  2015-07-23       Impact factor: 4.507
View more
  22 in total

Review 1.  Side effects of drugs for osteoporosis and metastatic bone disease.

Authors:  Michael Kriegbaum Skjødt; Morten Frost; Bo Abrahamsen
Journal:  Br J Clin Pharmacol       Date:  2018-10-17       Impact factor: 4.335

2.  Effect of Teriparatide Treatment on Circulating Periostin and Its Relationship to Regulators of Bone Formation and BMD in Postmenopausal Women With Osteoporosis.

Authors:  Fatma Gossiel; Jessica R Scott; Margaret A Paggiosi; Kim E Naylor; Eugene V McCloskey; Nicola F A Peel; Jennifer S Walsh; Richard Eastell
Journal:  J Clin Endocrinol Metab       Date:  2018-04-01       Impact factor: 5.958

3.  Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation.

Authors:  Sarah Davis; Emma Simpson; Jean Hamilton; Marrissa Martyn-St James; Andrew Rawdin; Ruth Wong; Edward Goka; Neil Gittoes; Peter Selby
Journal:  Health Technol Assess       Date:  2020-06       Impact factor: 4.014

4.  Long-term persistence with denosumab: real-world data from the Austrian Osteoporosis Clinic (AOC). A retrospective data analysis.

Authors:  Ewald Boschitsch; Oliver Naegele; Anita Klinger; Harald Brix-Samoylenko
Journal:  Osteoporos Int       Date:  2021-08-25       Impact factor: 4.507

5.  Elevated parathyroid hormone levels in older women treated for osteoporosis using denosumab.

Authors:  Abayomi N Ogunwale; Fariha Hameed; Luis Valdez; Jude des Bordes; Maryam Jamil; Nahid Rianon
Journal:  Eur Geriatr Med       Date:  2021-09-29       Impact factor: 1.710

6.  Teriparatide and denosumab combination therapy and skeletal metabolism.

Authors:  L Idolazzi; M Rossini; O Viapiana; V Braga; A Fassio; C Benini; V Kunnathully; S Adami; D Gatti
Journal:  Osteoporos Int       Date:  2016-06-01       Impact factor: 4.507

Review 7.  Denosumab is not associated with risk of malignancy: systematic review and meta-analysis of randomized controlled trials.

Authors:  D Rosenberg; T Avni; G Tsvetov; A Gafter-Gvili; T Diker-Cohen
Journal:  Osteoporos Int       Date:  2020-11-03       Impact factor: 4.507

Review 8.  Anabolic Agents for Postmenopausal Osteoporosis: How Do You Choose?

Authors:  Felicia Cosman; David W Dempster
Journal:  Curr Osteoporos Rep       Date:  2021-02-26       Impact factor: 5.096

9.  Early Effects of Abaloparatide on Bone Formation and Resorption Indices in Postmenopausal Women With Osteoporosis.

Authors:  David W Dempster; Hua Zhou; Sudhaker D Rao; Chris Recknor; Paul D Miller; Benjamin Z Leder; Miriam Annett; Michael S Ominsky; Bruce H Mitlak
Journal:  J Bone Miner Res       Date:  2021-01-28       Impact factor: 6.741

10.  Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates.

Authors:  P D Miller; N Pannacciulli; J P Brown; E Czerwinski; B S Nedergaard; M A Bolognese; J Malouf; H G Bone; J-Y Reginster; A Singer; C Wang; R B Wagman; S R Cummings
Journal:  J Clin Endocrinol Metab       Date:  2016-06-06       Impact factor: 5.958
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.